Haleon/HLN

$8.22

1.1%
-
1D1W1MYTD1YMAX

About Haleon

Haleon plc is a consumer healthcare company. The Company’s product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

Ticker

HLN

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Brian Mcnamara

Employees

24,000

Headquarters

Brentford, United Kingdom

Haleon Metrics

BasicAdvanced
$36.3B
Market cap
28.87
P/E ratio
$0.28
EPS
-
Beta
-
Dividend rate
1.85%
Dividend yield
$36.3B
$9.05
$7.70
5.8M
1.038
0.735
52.993
56.943
36.99%
7.37%
3.23%
6.37%
3.73%
28.873
2.58
16.532
1.85%
4.09%
-1.66%
4.54%
-2.97%

What the Analysts think about Haleon

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
15.57% upside
High $9.97
Low $9.03
$8.22
Current price
$9.50
Average price target

Haleon Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-0.1% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
£2.77B
-1.14%
Net income
£-3M
-100.82%
Profit margin
-0.1%
-100.77%

Haleon Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 36.29%
QuarterlyAnnual
Q4 23
Q1 24
Actual
£0.07
-
Expected
£0.10
£0.09
Surprise
-36.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Haleon stock?

Haleon (HLN) has a market cap of $36.51B as of April 21, 2024.

What is the P/E ratio for Haleon stock?

The price to earnings (P/E) ratio for Haleon (HLN) stock is 28.97 as of April 21, 2024.

Does Haleon stock pay dividends?

No, Haleon (HLN) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Haleon dividend payment date?

Haleon (HLN) stock does not pay dividends to its shareholders.

What is the beta indicator for Haleon?

Haleon (HLN) does not currently have a Beta indicator.

What is the Haleon stock price target?

The target price for Haleon (HLN) stock is $9.56, which is 16.3% above the current price of $8.22. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Haleon stock

Buy or sell Haleon stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing